IPM Take
Precision cardiology is no longer a conference slogan. Merck KGaA’s Saturnus Bio deal shows that major industry players are now placing early bets on rare genetic cardiomyopathies and targeted gene modulation. That is scientifically exciting. But it also exposes the policy gap. Most health systems still do not have routine cardiovascular genetic testing, enough genetic counsellors, scalable family screening, reimbursement clarity or data systems able to support genotype-defined care. The drug pipeline may be moving faster than the care pathway.
Executive Summary
Merck KGaA announced that it is collaborating with Versant Ventures to launch Saturnus Bio, a research-stage precision cardiology company focused on rare monogenic cardiomyopathies. The deal includes a USD 50 million upfront payment from Merck KGaA to fund Saturnus’ research activities, a minority equity stake, additional success-based preclinical milestones and Merck’s exclusive option to acquire Saturnus through a predetermined option payment and success-based earnouts.
Saturnus Bio will focus on targeted gene modulation approaches for rare genetic cardiomyopathies with high unmet need. Merck KGaA describes the area as a potential entry point for its cardiovascular business and as a market where there are no approved therapies directly targeting genetic drivers.
The move comes as precision cardiology is becoming more clinically visible. ESC cardiomyopathy guidelines provide a diagnostic framework for cardiomyopathies and patients’ relatives, while recent AHA policy work has emphasised the need for equitable implementation of genetic and genomic testing in cardiovascular disease. At the same time, approved cardiac myosin inhibitors such as mavacamten and aficamten are reshaping treatment for symptomatic obstructive hypertrophic cardiomyopathy, showing that targeted cardiac muscle therapies can reach the clinic.
The policy message is clear: genotype-defined cardiology will not scale through drug development alone. It will require genetic testing access, pre- and post-test counselling, family cascade screening, cardiac imaging, long-term surveillance, data governance and reimbursement models that recognise the clinical and familial implications of inherited heart disease.
Why it matters
- Policymakers and public authorities: Precision cardiology requires infrastructure. Genetic testing, family screening and surveillance pathways need to be built into cardiovascular services before targeted therapies arrive.
- Regulators: Gene-modulating cardiovascular therapies will require careful assessment of safety, durability, off-target effects, long-term follow-up and real-world monitoring.
- HTA bodies and payers: Value assessment cannot focus only on the treated individual. Inherited cardiomyopathy care affects relatives, cascade screening, prevention of sudden death and long-term heart failure costs.
- Clinicians and providers: Cardiologists will need stronger genomic literacy and clearer pathways for referral, variant interpretation, genetic counselling and family management.
- Patients and advocates: Genetic cardiomyopathy diagnosis can affect the whole family. Patients need access to counselling, privacy protections, psychosocial support and treatment pathways that do not stop at a genetic result.
Precision cardiology is starting to look like precision oncology did a decade ago.
First came the language: genetic risk, variant interpretation, inherited disease, family screening, molecular drivers. Then came the diagnostics. Then the biomarkers. Then industry began to move.
Merck KGaA’s new collaboration with Versant Ventures to launch Saturnus Bio is one of those signals.
The deal is not large by late-stage pharma standards. It is early. It is research-stage. It does not come with a Phase 3 readout, an approval filing or an imminent product launch. But it matters because of what it points toward: cardiology is moving from broad disease categories toward molecularly defined disease.
Saturnus Bio will focus on rare monogenic cardiomyopathies, using targeted gene modulation to address diseases driven by specific genetic causes. Merck KGaA is putting USD 50 million upfront into the build-to-buy structure, taking a minority equity stake and securing an exclusive option to acquire the company if the programme succeeds.
That structure says something important. Merck KGaA is not simply licensing a late-stage asset. It is helping build the biology early, while preserving the option to own the platform later. For rare cardiomyopathies, that is a strategic bet on the idea that genetic drivers can become drug targets.
This is where the story becomes bigger than one deal.
Inherited cardiomyopathies are not niche curiosities. They can lead to heart failure, arrhythmias, sudden cardiac death, repeated hospitalisation and lifelong surveillance. They also sit inside families. A diagnosis in one patient can have implications for siblings, children, parents and relatives who may be asymptomatic but at risk.
That makes precision cardiology clinically powerful and politically complicated.
The current system is not built for it.
In conventional cardiology, a patient is often managed by phenotype: hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, heart failure with reduced ejection fraction, preserved ejection fraction, obstruction or no obstruction. Precision cardiology asks a harder question: what is the mechanism, and does it matter for the patient and their family?
That requires testing. It requires interpretation. It requires counselling. It requires family communication. It requires follow-up over years. It requires access to imaging, electrophysiology, heart failure care and, increasingly, targeted therapies.
The 2023 ESC cardiomyopathy guidelines already recognised this shift by providing a diagnostic and treatment framework for patients with cardiomyopathies and their relatives. Subsequent European work on dilated cardiomyopathy family care has emphasised that genetic testing can guide cascade screening and that family members considering genetic testing should receive pre- and post-test counselling from trained professionals.
That is not administrative detail. It is the core of the pathway.
A genetic test without counselling can create confusion. A variant of uncertain significance can create anxiety without action. A pathogenic variant without family screening misses prevention. A family screening programme without access to imaging and follow-up becomes a dead end.
Precision cardiology only works if the system can act on precision.
This is why Merck KGaA’s move should not be read as a simple pipeline headline. It is a warning to payers and policymakers. The therapies may come, but the infrastructure is lagging.
There are already signs that cardiac muscle disease is becoming a more competitive therapeutic field. Mavacamten is approved for symptomatic obstructive hypertrophic cardiomyopathy in adults in the United States and Europe, and Bristol Myers Squibb has reported that FDA accepted a supplemental application for adolescent symptomatic obstructive HCM with priority review. In December 2025, FDA approved aficamten for adults with symptomatic obstructive HCM.
These drugs are not the same as targeted gene modulation for rare monogenic cardiomyopathies. They treat a disease mechanism in obstructive HCM rather than correcting the underlying genetic cause. But they show that cardiomyopathy is no longer treated only with beta blockers, calcium channel blockers, devices, surgery and late-stage heart failure care. The field is becoming molecular, targeted and commercially visible.
That visibility creates opportunity, but also inequality.
Who gets genetic testing? Who pays for it? Which gene panels are used? Who interprets variants? Who contacts relatives? Who covers cardiac MRI or serial echocardiography for genotype-positive relatives? Who protects patients from genetic discrimination or insurance anxiety? Who funds care coordination when the “patient” is effectively a family?
These are policy questions, not laboratory questions.
The AHA’s recent policy statement on genetic and genomic testing in cardiovascular disease points in the right direction by emphasising equitable implementation and the integration of testing into care and research while addressing ethical and disparity risks. But implementation remains patchy. Genetic counselling capacity is limited. Cardiologists vary in genomic training. Reimbursement policies differ. Many health systems still treat genetic testing as an add-on rather than a standard component of inherited cardiac disease care.
That gap will become harder to defend as targeted therapies develop.
A future gene-modulating therapy for a rare cardiomyopathy will not help patients who are never genetically diagnosed. It will not help relatives who are never offered cascade testing. It will not help communities where cardiology services are thin, where imaging access is delayed, or where genomic medicine exists only in academic centres.
This is the old precision medicine problem, now arriving in cardiology.
Innovation starts in specialised centres. Testing follows reimbursement. Reimbursement follows evidence. Evidence follows trial access. Trial access follows diagnosis. Diagnosis follows clinician suspicion and system capacity. Patients outside that chain stay invisible.
The danger is that precision cardiology becomes precise for the already-reached.
The policy response should start now.
First, inherited cardiomyopathy pathways should be commissioned as services, not left to individual champions. Every health system should define when to refer, when to test, who counsels, how relatives are contacted, and how genotype-positive or phenotype-negative individuals are monitored.
Second, reimbursement should recognise the family dimension. Payers often think in terms of one test, one patient, one intervention. Genetic cardiomyopathy does not work that way. The value may include preventing sudden death in a relative, avoiding unnecessary screening in non-carriers, guiding reproductive decisions, or identifying risk before heart failure develops.
Third, cardiovascular genetics needs workforce investment. Cardiologists do not all need to become geneticists, but they need enough genomic literacy to recognise red flags and refer appropriately. Genetic counsellors, specialist nurses, clinical geneticists and inherited cardiac disease clinics need sustainable funding.
Fourth, data systems need to support long-term surveillance. A genetic result can remain clinically relevant for decades. Variant classification can change. Family history can evolve. Patients may move across health systems. Precision cardiology needs data continuity, not one-off PDF reports buried in records.
Fifth, regulation and HTA will need to prepare for gene-modulating cardiac therapies. Safety questions will be different from conventional drugs. Follow-up may need to be long. Outcomes may need to include arrhythmias, heart failure progression, imaging markers, quality of life, family impact and prevention of catastrophic events.
Finally, equity must be built in from the start. Genetic datasets and variant interpretation have historically been stronger for populations better represented in research. Underrepresented groups can face more uncertain results, weaker evidence and lower access. If precision cardiology ignores this, it will reproduce the genomic inequities already seen in other fields.
Merck KGaA’s Saturnus Bio deal is early. Many early programmes fail. Targeted gene modulation in cardiomyopathy will face scientific, regulatory and clinical hurdles. There is no guarantee that this platform will produce approved therapies.
But as a signal, it is important.
It tells us that cardiovascular medicine is entering the same terrain as oncology and rare disease: molecular targets, smaller populations, higher prices, specialised diagnostics, family implications and pressure on payers to decide what counts as value.
The future of cardiology may be genetic.
The question is whether health systems will be ready before the therapies arrive, or whether patients will once again wait for policy to catch up with science.
